MHC Class II Restricted Innate-Like Double Negative T Cells Contribute to Optimal Primary and Secondary Immunity to

Summary

Although it is generally believed that CD4+ T cells mediate anti-Leishmania immunity, some studies suggest that CD3+CD4−CD8− (double negative, DN) T cells may play a more important role in regulating primary anti-Leishmania immunity. Here, we report that DN T cells extensively proliferate and produce effector cytokines in mice following primary and secondary L. major infections. Leishmania-reactive DN T cells utilize αβ T cell receptor (TCR) and are restricted by MHC class II molecules. Strikingly, DN T cells from healed mice display functional characteristics of protective anti-Leishmania memory-like cells: rapid and extensive proliferation, effector cytokine production in vitro and in vivo, and accelerated parasite control following secondary L. major challenge. These results directly identify DN T cells as important players in protective primary and secondary anti-L. major immunity in experimental cutaneous leishmaniasis.

Introduction

The spectrum of disease collectively called Leishmaniasis is caused by several species of protozoan parasites belonging to the genus Leishmania. The disease is currently endemic in 88 countries, affecting an estimated 12 million people with over 1.5–2 million new cases and 70,000 deaths each year [1]. Because Leishmania parasites reside mainly within macrophages, a strong cell-mediated immunity is required to control intracellular parasite replication and disease progression [2], [3], [4], [5], [6]. Experimental L. major infection in mice closely mimics the human cutaneous disease and is an excellent model for understanding the factors that regulate cell-mediated immunity. Resistance to cutaneous leishmaniasis is associated with strong IFN-γ response, which activates infected macrophages leading to nitric oxide and reactive oxygen species production and destruction of the intracellular parasites [4], [7], [8], [9].

Although it is generally believed that CD4⁺ T cells play a primary role in mediating anti-Leishmania immunity, a study suggests that they may be dispensable and that MHC II-restricted CD3⁺CD4⁻CD8⁻ (double negative, DN) T cells are critical for regulating primary anti-Leishmania immunity [10]. In addition, several studies have reported increased numbers of DN T cells in blood of Leishmania-infected patients [11], [12], dogs [13], and in spleens of Leishmania-infected mice [14]. These cells have been proposed to contribute to primary and vaccine-induced immunity against Leishmania. However, direct evidence implicating DN T cells in anti-Leishmania immunity has not yet been clearly documented. Here, we report for the first time, that infection with L. major leads to activation and proliferation of DN T cells in the draining lymph nodes (dLNs) and spleens of infected mice. These cells produce effector cytokines (IFN-γ and TNF), display functional characteristics of memory-like cells and contribute to optimal primary and secondary protection against L. major infection.

Results

DN T cells from healed mice proliferate and produce effector cytokines in response to L. major-infected BMDCs in vitro

Recovery from natural or experimental L. major infection is associated with strong T cell proliferation and IFN-γ production in spleens and dLNs. To investigate the contribution of CD4⁺ T cells in this process, we co-cultured CD8⁺ T cell-depleted splenocytes from healed mice with L. major-infected BMDCs in vitro. Surprisingly, we found in addition to CD4⁺ T cells, strong proliferative and IFN-γ responses by CD3⁺CD4⁻CD8⁻ (DN) T cells (Fig. 1A and Fig. S1A and B). Proliferating DN T cells also produced TNF (Fig 1B), IL-17 (Fig. S2A) and little IL-2 (Fig. 1D), suggesting they are polyfunctional in cytokine production. Indeed, most of the IFN-γ-producing DN cells also co-produced TNF (Fig. 1C). Interestingly, although DN T cells proliferate significantly more than CD4⁺ T cells, their quantitative ability to produce IFN-γ and TNF was significantly lower than those of CD4⁺ T cells (Fig. S2B–D). In addition, DN T cells also produced GrzB (Fig. 1E), suggesting they may perform effector functions in L. major-infected mice. DN T cells from L. major-infected mice did not proliferate or produce IFN-γ following stimulation with OVA-loaded DCs (Fig. 1F), but were activated by DCs pulsed with SLA or freeze-thawed L. major (Fig. 1F). Collectively, these results suggest that the proliferation and cytokine production by DN T cells from healed mice are L. major specific.

DN T cells proliferate and produce IFN-γ in vivo after rechallenge with L. major and display memory markers

Our co-culture system showed that Leishmania-specific DN T cells are activated following in vitro recall response. To determine whether DN T cells are activated in vivo, we adoptively transferred CFSE-labeled T cells from healed Thy1.2 mice into naive Thy1.1 mice that were then challenged with L. major the next day. Both CD4⁺ and DN T cells from healed donor mice showed extensive proliferation and IFN-γ production compared to those from naive mice (Fig. 2A–D). The in vivo relevance of DN T cell response was further confirmed by BrdU incorporation (Fig. 2E and F). Interestingly and similar to CD4⁺ T cells, the percentage of proliferating and IFN-γ-producing DN T cells in healed mice were significantly higher than those in naïve mice following L. major challenge, suggesting that DN T cells display functional characteristics of memory T cells (rapid proliferation and cytokine production). Indeed, we found that the percentage of DN T cells in lymph nodes (Fig 3A) of healed mice that express CD62L^hiCD44^hi (central memory-like) was significantly higher (p<0.05) than those in naive mice (Fig. 3B). Following adoptive transfer of whole T cells from healed mice and subsequent L. major challenge, almost all the proliferating donor CD4⁺ T cells downregulated their CD62L expression (i.e. were CD62L^lo). In contrast, the proliferating DN T cells contained an almost equal proportion of CD62L^lo and CD62L^hi populations (Fig. 3C). In addition, more DN T cells were CD62L^hiCD44^hi compared to CD4⁺ T cells (Fig. 3D).

DN T cells predominately express αβ-TCR and do not have regulatory properties

In addition to αβ T cells, NKT and γδ T cells also do not express CD4 and CD8 molecules. To determine whether Leishmania-reactive DN T cells are NKT and γδ T cells, we assessed the expression of αβ, γδ and NK1.1 molecules on DN T cells by flow cytometry. As shown in Fig. 4A, DN T cells predominately (> 90%) expressed αβ TCR and not NK1.1 and γδ molecules, indicating that they are not NKT or γδ T cells. To further determine whether DN T cells are CD4⁺ or CD8⁺ T cells that have down-regulated their surface molecules following activation, we assessed highly enriched (> 99% purity, Fig. S3) DN, CD4⁺ and CD8⁺ T cells for CD4 and CD8 transcripts by RT-PCR. DN T cells did not express CD4 and CD8 mRNA (Fig. 2B), suggesting they are not CD4⁺ or CD8⁺ T cells that have down-regulated their surface molecules. In addition, highly purified CD4⁺, CD8⁺ and DN T cells maintained their respective phenotypes following in vitro restimulation for 5 days with L. major-infected BMDCs (Fig. 4C). To determine whether Leishmania-reactive DN T cells display regulatory properties as previously reported in other systems [12], [15], [16], we co-cultured CD4⁺ and DN T cells with L. major-infected BMDCs and assessed CD4⁺ T cell proliferation and IFN-γ production by flow cytometry. DN T cells did not affect CD4⁺ cell proliferation and IFN-γ production (Fig. 4D), suggesting that they do not exhibit regulatory/suppressive properties.

DN T cells are mostly restricted by MHC II

To determine whether Leishmania-reactive DN T cells are restricted by MHC II molecule, we co-cultured highly enriched T cells from healed mice with infected BMDCs in the presence or absence of anti-MHC II antibodies. Anti-MHC II antibodies blocked proliferation and IFN-γ production by both CD4⁺ and DN T cells in a dose-dependent manner (Fig. 5A). In addition, L. major-infected BMDCs from MHC II KO mice failed to induce proliferation and IFN-γ production by DN and CD4⁺ T cells (Fig. 5B). In contrast, proliferation and IFN-γ production by DN T cells were minimally affected following co-culture with infected BMDCs from CD1d KO mice (Fig. 5C), confirming that DN T cells are mostly restricted by MHC II molecules.

DN T cells are activated during primary L. major infection

We found that Leishmania-reactive DN T cells are recalled in healed mice following L. major challenge in vitro and in vivo suggesting that they may be induced following primary infection. To determine this, we assessed CD4⁺ and DN T cells response in the dLNs and spleens of infected mice C57BL/6 mice at different times after infection corresponding to early, peak and resolution of lesion progression (Fig. 6A). As expected, there was strong CD4⁺ T cell response (proliferation and IFN-γ production, Fig. 6B) at all times (3, 6 and 12 weeks) post-infection. Similarly, DN T cells from infected mice also strongly proliferated and produced IFN-γ following restimulation with infected BMDCs (Fig. 6C). In contrast, CD4⁺ and DN T cells from naïve mice did not proliferate or produce IFN-γ upon stimulation with L. major-infected BMDCs (Fig. 6B and C). Collectively, these results show that Leishmania-reactive DN T cells are induced during primary L. major infection and could contribute to anti-Leishmania immunity.

DN T cells contribute to optimal primary and secondary immunity against L. major

To determine if DN T cells contribute to primary immunity against L. major, we selectively depleted CD4⁺ and CD8⁺ or all T cells by treatment with anti-CD4/CD8 or anti-Thy1.2 mAbs, respectively, during the course of primary L. major infection (Fig. S4). Mice depleted of both CD4⁺ and CD8⁺ T cells still had some IFN-γ-producing CD3⁺ DN T cells (Fig. 7A and 7B) and harbor significantly (p<0.01) lower parasite burden (Fig. 7C) compared to those depleted of all T cells (by anti-Thy1.2 mAb treatment), indicating that DN T cells contribute to optimal control of parasite proliferation during primary L. major infection.

Next, we used both in vitro and in vivo approaches to investigate whether DN T cells contribute to secondary anti-Leishmania immunity. Highly purified DN T cells from healed (but not naïve) mice significantly (p<0.05) inhibited parasite proliferation in infected BMDMs and this effect was comparable to those of CD4⁺ T cells (Fig. S5A and B). These results provide direct in vitro evidence that DN T cells could control parasite growth in L. major-infected BMDMs.

Next, we used two different experimental approaches to determine whether DN T cells contribute to secondary anti-Leishmania immunity in vivo. First, we selectively depleted CD4⁺ and CD8⁺ or all CD3⁺ T cells (as in Fig. 7A above) in healed mice and after 24 hr, rechallenged them with L. major. As shown in Fig. 7D, CD4⁺ and CD8⁺ T cells-depleted mice, which still had DN T cells, retained some level of infection-induced resistance as evidenced by significantly (p<0.01) lower parasite burden compared to naïve mice (primary infection). In contrast, depletion of all CD3⁺ T cells completely abrogated secondary immunity (Fig. 7D). Second, we assessed the ability of highly enriched (purity > 96%, Fig. S6) DN T cells from healed mice to protect naïve animals against virulent L. major challenge. Adoptively transferred DN T cells from healed mice protected naïve mice against virulent L. major challenge as evidenced by significantly lower parasite burden (Fig. 7E). Collectively, these in vitro and in vivo observations strongly implicate Leishmania-reactive DN T cells in contributing to optimal anti-Leishmania immunity in mice.

Increased transcriptional activity of innate genes in Leishmania-reactive DN T cells

Apart from lacking CD4 molecules, DN T cells display functional characteristics similar to CD4⁺ T cells (MHC-II restriction, proliferation, IFN-γ production and parasite control). To further investigate how Leishmania-reactive DN T cells differ from CD4⁺ T cells, we compared the transcriptional profile of proliferating DN and CD4⁺ T cells following restimulation with L. major-infected BMDCs. Although most of the 84 mouse innate and adaptive immune genes showed similar pattern and level of expression in both cell types, some genes were preferentially upregulated or downregulated in DN T cells compared to CD4⁺ T cells (Fig. 8A). The gene transcripts showing ≥ 2 folds difference in DN T cells were further analyzed and validated by quantitatively real-time PCR (Fig 8B and C). Interestingly, most of the upregulated transcripts in DN T cells were genes associated with innate immune responses, including C3, Mac-1 (CD11b), myeloperoxidase (Mpo), lysozyme, etc. In contrast, the downregulated transcripts (relative to CD4⁺ T cells) included genes associated with adaptive immunity, including CCR4, Foxp3, Gata-3, etc. Collectively, these results suggest that despite mediating anti-Leishmania immunity (akin to CD4⁺ T cells), Leishmania-reactive DN T cells are phenotypically distinct from conventional CD4⁺ T cells.

Discussion

We show here that DN T cells proliferate and produce effector cytokines in secondary lymphoid organs of mice following primary and secondary L. major challenges. DN T cells from healed mice display functional characteristics of anti-Leishmania memory-like cells: they rapidly proliferate and produce effector cytokines (TNF and IFN-γ) in response to L. major challenge in vitro and in vivo and mediate infection-induced immunity (rapid protection) following adoptive transfer in vivo. Leishmania-reactive DN T cells express predominantly αβ TCR, are restricted by MHC class II molecules, lack immunoregulatory properties and display transcriptional profile distinct from conventional CD4⁺ T cells. To the best of our knowledge, this is the first extensive characterization and demonstration of the protective ability of Leishmania-reactive DN T cells in vitro and in vivo.

It is generally believed that CD4⁺ T cells play a dominant role in anti-Leishmania immunity. However, the finding that CD4 deficient mice were resistant while MHC class II deficient mice were highly susceptible to L. major challenged this dogma [10] and suggests that MHC II-restricted CD4⁻CD8⁻ T cells may be more important in regulating primary anti-Leishmania immunity. Indeed, several studies have reported the expansion of CD3⁺CD4⁻CD8⁻ (DN) T cells in the blood of Leishmania-infected patients and dogs, and in spleens of Leishmania-infected mice [11], [12], [13], [14]. These cells have been proposed to contribute to primary and vaccine-induced immunity although a concrete evidence implicating them in immunity has not yet been demonstrated. Our studies directly show the importance of Leishmania-reactive DN T cells in mediating optimal primary and secondary anti-Leishmania immunity in mice.

The precise origin and development of peripheral DN T cells is not clearly understood and is controversial. Some reports suggest that DN T cells originate in the thymus by escaping negative selection [17], [18], [19]. In contrast, several reports suggest that DN T cells are generated in the periphery rather than in the thymus [19], [20], [21], [22]. These cells comprise about 1–5% of total T cells in non-transgenic mice and in humans [11], [23] making them difficult to isolate and subsequently study. TCR transgenic [24] or lpr (Fas mutation) mice [19], [25], which present increasing accumulation of DN T cells are widely used to investigate the function and developmental origin of DN T cells. DN T cells have been shown to influence long-term allograft survival [24], [26], [27], prevent the development of autoimmune disease [28], [29], [30], and contribute to control of intracellular pathogens [31], [32]. In addition, DN T cells have been shown to possess immunoregulatory and alloreactive properties, inhibit autoreactive CD4⁺ T cells and mediate MHC I-restricted killing of allogenic target cells [20], [24], [25]. Our studies show that Leishmania-reactive DN T cells are restricted by MHC class II and may not have immunoregulatory properties because they failed to suppress CD4⁺ T cell proliferation in vitro (Fig. 4D). Rather, a large percentage of proliferating DN T cells produced IFN-γ, TNF, IL-17 and GrzB, which is consistent with their effector functions as seen in other studies [11], [12], [29].

Previous studies that have reported the expansion and possible protective role of DN T cells in leishmaniasis focused mainly on primary Leishmania infection [11], [12], [13], [14]. We extend these studies during secondary immunity by showing rapid expansion and effector functions (cytokine production and parasite control) by DN T cells following challenge infection. Healed mice had more proliferating and IFN-γ-producing DN T cells compared with naive mice following L. major challenge (Fig. 2), and adoptive transfer of DN T cells from healed (but not naïve mice) rapidly protected naïve mice against virulent L. major change. Moreover, DN T cells from healed mice expressed high levels of CD44 and majority of them were CD62L^hiCD44^hi, which are characteristics markers expressed by central memory-like cells. Collectively, these results suggest that DN T cells display functional characteristics of memory cells and contribute to optimal secondary immunity against L. major.

How do DN T cells mediate their anti-Leishmania immunity? We speculate that this may be related in part to their ability to produce IFN-γ and TNF, key cytokines that activate infected macrophages leading to intracellular parasite killing. Indeed, we found that Leishmania-reactive DN T cells in the spleens and lymph nodes are highly proliferative and produce IFN-γ, TNF and granzyme B. Importantly, we also found that DN T cells from immune mice were recruited to and proliferate at the infected footpads (Fig. S7). In addition, our in vitro co-culture experiments with infected BMDMs and highly enriched DN T cells show that suppression of parasite proliferation was associated with increased nitric oxide production, a key effector molecule that mediate destruction of parasites in infected cells.

The findings that DN T cells mediate comparable (or even superior) protection against L. major in vitro and in vivo may challenge the dogma that CD4⁺ T cells are the major T cell subset that mediates anti-Leishmania immunity. Indeed, the proliferation of DN T cells was either comparable or sometimes higher than those of CD4⁺ T cells following in vitro or in vivo L. major challenge (see Figs. 1–3). Interestingly, although the percentage of IFN-γ-producing DN T cells was sometimes higher than those of CD4⁺ T cells, their MFI was significantly lower (Fig. 1C), an observation that explain the relatively lower IFN-γ transcripts in DN compared to CD4⁺ T cells (Fig. 8). In addition, the numbers of Leishmania-reactive CD4⁺ T cells were quantitatively (∼ 3–4 fold) higher than those of DN T cells. Thus, despite their superior proliferative response, DN T cells may still play a subordinate role to CD4⁺ T cells in vivo. Furthermore, it is conceivable that CD4⁺ T cells may be required for proper activation and effector functions of DN T cells. In line with this, we have observed that proliferation and IFN-γ production by highly enriched DN T cells is impaired in cultures devoid of immune CD4⁺ T cells in vitro and in vivo (Fig. S8). It is conceivable that DN T cells may assume increased roles in the absence of CD4⁺ T cells. For example, SIV infection in nonhuman primates does not result in immune dysfunction and progression to simian AIDS because DN T cells partially compensate for defective CD4⁺ T cell functions upon SIV-induced CD4⁺ T cell depletion in these animals [33], [34]. Similarly, a strong DN T cell-mediated HIV Gag-specific response has been associated with seronegativity in HIV-exposed individuals [35].

It is interesting that the expression of genes associated with innate immune responses including C3, were significantly higher in Leishmania-reactive DN T cells than in CD4⁺ T cells. While commonly associated with initiation of inflammation and critical molecule involved in first line of defense against pathogens, the complement proteins, particularly C3 and its degradation fragments are also known to prominently influence the adaptive immunity [36], [37]. Recent studies have been shown that some subset of T cells express C3 and that its intracellular activation is not only required for homeostatic T cell survival [38], but also in optimal Th1 induction and differentiation into effector cytokine (particularly IFN-γ) production [38], [39]. It is conceivable that C3-expressing DN T cells in L. major-infected mice might be involved in IFN-γ production leading to effective macrophage activation, nitric oxide production and parasite killing.

Collectively, our studies provide direct evidence for DN T cells in mediating anti-Leishmania immunity akin to CD4⁺ T cells. We propose that DN T cells complement CD4⁺ T cells to mediate efficient primary and secondary anti-Leishmania immunity in mice. In the absence of DN T cells, the induction of effective anti-Leishmania immunity may be either delayed or impaired. In a recent preliminary study, we observed impaired induction of DN T cells in spleens and draining lymph nodes of L. major-infected highly susceptible BALB/c mice. It would be interesting to determine whether the susceptibility of BALB/c mice to L. major infection is related in part to this impaired expansion of DN T cells. Collectively, our studies clearly identify DN T cells as important subset of T cells that contribute to optimal anti-Leishmania immunity.

Materials and Methods

Ethics statement

All mice were kept at the University of Manitoba Central Animal Care Services (CACS) facility in accordance to the Canadian Council for Animal Care guidelines. The University of Manitoba Animal Use Ethics Committee approved all studies involving animals, including infection, humane endpoints, euthanasia and collection of samples.

Mice

Six to 8 wk-old female C57BL/6 (Thy1.2) mice were obtained from Charles River, St Constante PQ, Canada. Thy1.1 and MHC class II deficient (MHC II KO) C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Female CD1d deficient C57BL/6 mice were kindly supplied by Dr. Xi Yang from a breeding colony maintained at the University of Manitoba Central Animal Care Services (CACS) Facility.

Infection protocol and parasite quantification

Leishmania major parasites (MHOM/80/Fredlin) were grown in M199 culture medium (Sigma, St. Louis, MO) supplemented with 20% heat inactivated FBS (HyClone, Logan, UT), 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. For infection, mice were injected with 2×10⁶ (primary infection) or 5×10⁶ (secondary infection) stationary-phase promastigotes in 50 µl PBS suspension into the right (primary) or left (secondary) hind footpad. Lesion sizes were monitored weekly by measuring footpad swelling with calipers. Parasite burden in the infected footpads was determined by limiting dilution assay. Parasite titers were determined from the highest dilution at which growth was visible.

Bone marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) and in vitro infection

Bone marrow cells were isolated from the femur and tibia of naïve C57BL/c mice and differentiated into macrophages using complete medium supplemented with 30% L929 cell culture supernatant as previously described [40]. BMDCs were differentiated in petri dishes in the presence of rmGM-CSF (20 ng/ml; Peprotech, Rocky Hill, NJ). BMDMs and BMDCs were infected at a cell-to-parasite ratio of 1∶5 and after 6 hr, free parasites were washed away and infected BMDCs were used to stimulate purified CD3⁺, CD4⁺ or DN T cells from naïve or healed mice in vitro. To assess the ability of CD4⁺ or DN T cells to control parasite proliferation, infected BMDMs were co-cultured with CD4⁺ or DN T cells and parasite proliferation in infected BMDMs was determined at different times by counting Giemsa-stained cytospin preparations under light microscope at ×100 (oil immersion) objective.

In vitro recall responses

Infected mice were sacrificed and spleens and dLNs were collected and made into single-cell suspensions. Cells were labeled with CFSE dye (1.5 mM; Molecular Probes, Eugene, OR) and resuspended at a concentration of 2×10⁶ cells per milliliter in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 5×10⁻⁵ M 2-mercaptoethanol (complete medium), plated with 100 µl per well in 96-well tissue culture plates, and stimulated with infected BMDCs (BMDC: T cell = 1∶100) or soluble anti-CD3/CD28 mAb (1 µg/ml; BioLegend, San Diego, CA). After 5 days, proliferation and cytokine production were determined by flow cytometry. In some experiments, CFSE-labeled T cells from spleens and dLNs of infected mice were co-cultured with L. major-infected WT, MHC II KO, or CD1d KO BMDCs for 5 days, stimulated with PMA, BFA and ionomycin for 4–6 hr and proliferation, IFN-γ, TNF, IL-2, IL-17 and GrzB expression by different T cell subsets were analyzed by flow cytometry. In some experiments, anti-MHC II antibodies were used to block MHC II-TCR interaction in vitro.

Purification of T cell subsets, cell labeling and adoptive transfer experiments

Healed (> 12 weeks post-infection) Thy1.2 C57BL/6 mice were sacrificed and single-cell suspensions from the dLNs and spleens were made. T cells (Thy1.2⁺) were enriched by positive selection using mouse CD90.2 (Thy1.2) selection kit according to the manufacturer's protocols (StemCell Technologies, Vancouver, BC). Enriched T cells (> 98% purity) were labeled with CFSE dye, and 10⁷ cells were adoptively transferred into naive congenic (Thy1.1) mice by tail vein injection. After 24 hr, the recipient mice were challenged with 5×10⁶ L. major, sacrificed after 7 days and cell proliferation and IFN-γ expression by donor (Thy1.2) cells in the dLNs and spleens were determined directly ex vivo.

Enrichment of DN T cells

For in vitro co-culture experiments, DN (CD3⁺CD4⁻CD8⁻) and CD4⁺ T cells were purified from pooled spleens and dLNs of healed or naïve mice by cell sorting (FACSAria III, BD Biosciences). For in vivo adoptive transfer studies, DN T cells were enriched using a combination of in vivo depletion and positive selection. Briefly, L. major-infected and healed mice (> 12 weeks post-infection) were first injected with 200 µl GK1.5 and TIB210 ascites (i.p) to deplete CD4⁺ and CD8⁺ cells. After 48 hr, DN T cells were purified using mouse CD90.2 selection kit (StemCell Technologies, Vancouver, BC). Enriched DN T cells were > 99% negative for CD4 and CD8 expression and > 95% positive for CD3 by flow cytometry.

Isolation of cells from infected footpads

To assess the numbers (percentages) and proliferation of DN T cells at the site of infection, CFSE-labeled whole T cells from L. major-infected Thy1.2 mice were adoptively transferred into naïve Thy1.1 mice that were then challenged with L. major. After 7 days, recipient mice were sacrificed and donor cells were recovered from the footpads as we previously described [41]. Briefly, the footpads were disinfected in 70% ethanol, the skins were peeled off and homogenized gently in PBS with tissue grinders. The crude homogenates were resuspended in 7 ml of cold PBS, carefully layered on top of 5 ml Ficoll and the infiltrating cells were separated by centrifugation according to the manufacturer's suggested protocols. The cells were collected, resuspended in 5 ml complete medium, counted, stained directly for expression of various cell surface markers and analyzed by flow cytometer by gating on Thy1.2⁺ donor cells.

RT-PCR, PCR array and qPCR

For reverse transcription-PCR (RT-PCR), cells from spleens of healed mice were stained with fluorescent-conjugated anti-CD3, anti-CD4 and anti-CD8 antibodies. CD4, CD8 and DN T cells were sorted to high purity by gating on CD3⁺ cells. CD4, CD8 and GAPDH gene expression in sorted cells were analyzed by RT-PCR. For PCR array, CFSE-labeled whole spleen cells from healed mice were stimulated with L. major-infected BMDCs for 5 days and proliferating (CFSE^lo) CD4⁺ and DN T cells were purified by cell sorting. Eighty-four innate and adaptive immune genes in CD4⁺ and DN T cells were analyzed with Mouse Innate & Adaptive Immune Responses PCR Array kit (Qiagen, Frederick, MD). PCR array was performed by a real-time cycler (Bio-Rad CFX96) and analyzed with web-based PCR Array Data Analysis Software (Qiagen, Frederick, MD). To quantify gene expression levels, equal amounts of cDNA were mixed with SYBR Green PCR master mix (Toyobo, Osaka, Japan) and primers specific for the gene of interest (Table S1). 18S rRNA was amplified as an internal control.

BrdU treatment

Naïve and healed mice were injected with 2 mg of BrdU i.p. per mouse and then challenged with 5×10⁶ L. major in the next day. BrdU solution was prepared in sterile water, protected from light exposure, and changed daily. The night before the assay, mice were injected i.p. with 0.8 mg of BrdU in PBS. The next day, mice were sacrificed, spleens were harvested and BrdU staining was performed using BrdU Staining Kit according to the manufacturer's suggested protocol (BD PharMingen).

Antibody depletion in vivo

Healed mice were depleted of CD4 and/or CD8 T cells by injecting i.p. 200 µl ascites containing anti-CD4 (GK1.5) or anti-CD8 (TIB 210) mAb (or both) per mouse or depleted of total T cells by injecting i.p. 100 µg anti-Thy1.2 mAb (TIB 107) per mouse, once a week, and then challenged with 5×10⁶ L. major.

Statistics

Data are presented as means and standard error of mean (SEM). Two-tailed Student's t-test or ANOVA were used to compare means and SEM between groups using GraphPad Prism software. Differences were considered significant at p<0.05.

Supporting Information

Attachment 1

Attachment 2

Attachment 3

Attachment 4

Attachment 5

Attachment 6

Attachment 7

Attachment 8

Attachment 9